[Comment] Rapid remission and effect on organ manifestations with anifrolumab

In The Lancet Rheumatology, Chiara Tani and colleagues1 report an interim analysis of a large real-world observational study of patients with systemic lupus erythematosus (SLE) treated with anifrolumab. Anifrolumab is a monoclonal antibody that blocks the common receptor of all type I interferons—ie, all interferons but interferon-γ (type II interferon) and the λ-interferons (type III interferons). Anifrolumab was approved for SLE treatment in 2021 by both the US Food and Drug Administration and the European Medicines Agency.